Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers-Reference-Cited by-同舟云学术

Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers

Published:1980 Issue:4 Volume:17 Page:305-308
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Abshagen U.,Sp�rl-Radun S.,Marinow J.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/BF00625805.pdf

Reference15 articles.

1. Abshagen U, Bablok W, Koch K, Lang PD, Schmid HAE, Senn M, Stork H (1979) Disposition Pharmacokinetics of Bezafibrate in Man. Eur J Clin Pharmacol 16: 31?38

2. Arntz HR, Klemens UH, Lang PD, Vollmar J (1978) Vergleich von Clofibrat und Bezafibrat bei Hyperlipoproteinämie Typ IIa und IIb. Med Klin 73: 1731?1737

3. Bolzano K, Krempler F, Schellenberg B, Schlierf G (1979) Eine vergleichende Studie von Bezafibrat und Clofibrat bei Patienten vom Typ IIB und IV. Acta Med Austriaca

4. Endele R (1978) A gas chromatographic method for the determination of bezafibrate. J Chromatogr 154: 261?263

5. Gugler R (1978) Clinical pharmacokinetics of hyperlipidaemic drugs. Clin Pharmacokinet 3: 425?539

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bezafibrate activation of PPAR drives disturbances in mitochondrial redox bioenergetics and decreases the viability of cells from patients with VLCAD deficiency;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2021-06

2. Treatment Opportunities in Patients With Metabolic Myopathies;Current Treatment Options in Neurology;2017-09-21

3. Bezafibrate in skeletal muscle fatty acid oxidation disorders: A randomized clinical trial;Neurology;2014-01-22

4. Relaxation of rat thoracic aorta by fibrate drugs correlates with their potency to disturb intracellular calcium of VSMCs;Vascular Pharmacology;2012-03

5. Using the fish plasma model for comparative hazard identification for pharmaceuticals in the environment by extrapolation from human therapeutic data;Regulatory Toxicology and Pharmacology;2011-12